Membrane Interactions of Oligomeric Alpha-Synuclein: Potential Role in Parkinson's Disease

Current Protein and Peptide Science

Volumn 11, Issue 5, 2010, Pages 334-342

  van Rooijen, Bart D ^a   Claessens, Mireille M A E ^a   Subramaniam, Vinod ^a  

^a UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

synuclein; Amyloid; Disruption; Membrane; Oligomer; Parkinson's disease; Permeabilization; Pore

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; OLIGOMER;

ALZHEIMER DISEASE; ARTICLE; CELL INCLUSION; DOPAMINERGIC NERVE CELL; GENE MUTATION; LEWY BODY; MEMBRANE PERMEABILITY; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN INTERACTION;

ALPHA-SYNUCLEIN; ANIMALS; CELL MEMBRANE; HUMANS; PARKINSON DISEASE; PROTEIN STRUCTURE, QUATERNARY;

EID: 77957904174     PISSN: 13892037     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920310791330659     Document Type: Article

References (164)

1. de Rijk, M.C.; Breteler, M.M.; Graveland, G.A.; Ott, A.; Grobbee, D.E.; van der Meché, F.G.; Hofman, A. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology, 1995, 45, 2143-2146.
2. Braak, H.; Del Tredici, K.; Rüb, U.; de Vos, R.A.I.; Steur, E.; Braak, E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging, 2003, 24, 197-211.
3. Samii, A.; Nutt, J.G.; Ransom, B.R. Parkinson's disease. Lancet, 2004, 363, 1783-1793.
4. Lewy, F.H. In Paralysis Agitans. Handbuch der Neurologie; Lewandowsski, M.; Ed. 1912; pp 920-933.
5. Olanow, C.W.; Watts, R.L.; Koller, W.C. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology, 2001, 56, S1-S88.
6. Dekker, M.C.J.; Bonifati, V.; van Duijn, C.M. Parkinson's disease: piecing together a genetic jigsaw. Brain, 2003, 126, 1722-1733.
7. Belin, A.C.; Westerlund, M. Parkinson's disease: a genetic perspective. FEBS J., 2008, 275, 1377-1383.
8. Gorell, J.M.; Johnson, C.C.; Rybicki, B.A.; Peterson, E.L.; Kortsha, G.X.; Brown, G.G.; Richardson, R.J. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology, 1999, 20, 239-247.
9. Gorell, J.M.; Johnson, C.C.; Rybicki, B.A.; Peterson, E.L.; Richardson, R.J. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology, 1998, 50, 1346-1350.
10. Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.; Trojanowski, J.Q.; Jakes, R.; Goedert, M. Alpha-synuclein in Lewy bodies. Nature, 1997, 388, 839-840.
11. Polymeropoulos, M.H.; Lavedan, C.; Leroy, E.; Ide, S.E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; Boyer, R.; Stenroos, E.S.; Chandrasekharappa, S.; Athanassiadou, A.; Papapetropoulos, T.; Johnson, W.G.; Lazzarini, A.M.; Duvoisin, R.C.; Di Iorio, G.; Golbe, L.I.; Nussbaum, R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 1997, 276, 2045-2047.
12. Krüger, R.; Kuhn, W.; Müller, T.; Woitalla, D.; Graeber, M.; Kösel, S.; Przuntek, H.; Epplen, J.T.; Schöls, L.; Riess, O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet., 1998, 18, 106-108.
13. Zarranz, J.J.; Alegre, J.; Gómez-Esteban, J.C.; Lezcano, E.; Ros, R.; Ampuero, I.; Vidal, L.; Hoenicka, J.; Rodriguez, O.; Atarés, B.; Llorens, V.; Gomez Tortosa, E.; del Ser, T.; Muñoz, D.G.; de Yebenes, J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol., 2004, 55, 164-173.
14. Chartier-Harlin, M.C.; Kachergus, J.; Roumier, C.; Mouroux, V.; Douay, X.; Lincoln, S.; Levecque, C.; Larvor, L.; Andrieux, J.; Hulihan, M.; Waucquier, N.; Defebvre, L.; Amouyel, P.; Farrer, M.; Destée, A. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet, 2004, 364, 1167-9.
15. Singleton, A.B.; Farrer, M.; Johnson, J.; Singleton, A.; Hague, S.; Kachergus, J.; Hulihan, M.; Peuralinna, T.; Dutra, A.; Nussbaum, R.; Lincoln, S.; Crawley, A.; Hanson, M.; Maraganore, D.; Adler, C.; Cookson, M.R.; Muenter, M.; Baptista, M.; Miller, D.; Blancato, J.; Hardy, J.; Gwinn-Hardy, K. alpha-Synuclein locus triplication causes Parkinson's disease. Science, 2003, 302, 841.
16. Meredith, G.E.; Kang, U.J. Behavioral models of Parkinson's disease in rodents: a new look at an old problem. Mov. Disord., 2006, 21, 1595-1606.
17. Feany, M.B.; Bender, W.W. A Drosophila model of Parkinson's disease. Nature, 2000, 404, 394-398.
18. [18] van Ham, T.J.; Thijssen, K.L.; Breitling, R.; Hofstra, R.M.W.; Plasterk, R.H.A.; Nollen, E.A.A. C-elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging. PLoS Genet., 2008, 4(3), e1000027.
19. Clayton, D.F.; George, J.M. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends. Neurosci., 1998, 21, 249-254.
20. Bayer, T.A.; Jäkälä, P.; Hartmann, T.; Egensperger, R.; Buslei, R.; Falkai, P.; Beyreuther, K. Neural expression profile of alpha- synuclein in developing human cortex. Neuroreport, 1999, 10, 2799-2803.
21. Iwai, A.; Masliah, E.; Yoshimoto, M.; Ge, N.F.; Flanagan, L.; Desilva, H.A.R.; Kittel, A.; Saitoh, T. The precursor protein of non-A-Beta component of Alzheimer's-disease amyloid is a presynaptic protein of the central-nervous-system. Neuron, 1995, 14, 467-475.
22. Murphy, D.D.; Rueter, S.M.; Trojanowski, J.Q.; Lee, V.M.Y. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci., 2000, 20, 3214-3220.
23. Kahle, P.J.; Neumann, M.; Ozmen, L.; Muller, V.; Jacobsen, H.; Schindzielorz, A.; Okochi, M.; Leimer, U.; van der Putten, H.; Probst, A.; Kremmer, E.; Kretzschmar, H.A.; Haass, C. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J. Neurosci., 2000, 20, 6365-6373.
24. Yu, S.; Li, X.; Liu, G.; Han, J.; Zhang, C.; Li, Y.; Xu, S.; Liu, C.; Gao, Y.; Yang, H.; Ueda, K.; Chan, P. Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody. Neuroscience, 2007, 145, 539-555.
25. Goers, J.; Manning-Bog, A.B.; McCormack, A.L.; Millett, I.S.; Doniach, S.; Di Monte, D.A.; Uversky, V.N.; Fink, A.L. Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry, 2003, 42, 8465-8471.
26. Tofaris, G.K.; Spillantini, M.G. Physiological and pathological properties of alpha-synuclein. Cell. Mol. Life Sci., 2007, 64, 2194-2201.
27. Chandra, S.; Fornai, F.; Kwon, H.B.; Yazdani, U.; Atasoy, D.; Liu, X.R.; Hammer, R.E.; Battaglia, G.; German, D.C.; Castillo, P.E.; Südhof, T.C. Double-knockout mice for alpha- and beta- synucleins: Effect on synaptic functions. Proc. Natl. Acad. Sci. USA, 2004, 101, 14966-14971.
28. Abeliovich, A.; Schmitz, Y.; Fariñas, I.; Choi-Lundberg, D.; Ho, W.H.; Castillo, P.E.; Shinsky, N.; Verdugo, J.M.G.; Armanini, M.; Ryan, A.; Hynes, M.; Phillips, H.; Sulzer, D.; Rosenthal, A. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron, 2000, 25, 239-252.
29. Cabin, D.E.; Shimazu, K.; Murphy, D.; Cole, N.B.; Gottschalk, W.; McIlwain, K.L.; Orrison, B.; Chen, A.; Ellis, C.E.; Paylor, R.; Lu, B.; Nussbaum, R.L. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci., 2002, 22, 8797-8807.
30. Dauer, W.; Kholodilov, N.; Vila, M.; Trillat, A.C.; Goodchild, R.; Larsen, K.E.; Staal, R.; Tieu, K.; Schmitz, Y.; Yuan, C.A.; Rocha, M.; Jackson-Lewis, V.; Hersch, S.; Sulzer, D.; Przedborski, S.; Burke, R.; Hen, R. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. USA, 2002, 99, 14524-14529.
31. Wersinger, C.; Sidhu, A. Attenuation of dopamine transporter activity by alpha-synuclein. Neurosci. Lett., 2003, 340, 189-192.
32. Ahn, B.H.; Rhim, H.; Kim, S.Y.; Sung, Y.M.; Lee, M.Y.; Choi, J.Y.; Wolozin, B.; Chang, J.S.; Lee, Y.H.; Kwon, T.K.; Chung, K.C.; Yoon, S.H.; Hahn, S.J.; Kim, M.S.; Jo, Y.H.; Min, D.S. A synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells. J. Biol. Chem., 2002, 277, 12334-12342.
33. Davidson, W.S.; Jonas, A.; Clayton, D.F.; George, J.M. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem., 1998, 273, 9443-9449.
34. Hashimoto, M.; Hsu, L.J.; Rockenstein, E.; Takenouchi, T.; Mallory, M.; Masliah, E. alpha-synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress- signaling pathway in neuronal cells. J. Biol. Chem., 2002, 277, 11465-11472.
35. Quilty, M.C.; King, A.E.; Gai, W.P.; Pountney, D.L.; West, A.K.; Vickers, J.C.; Dickson, T.C. Alpha-synuclein is upregulated in neurones in response to chronic oxidative stress and is associated with neuroprotection. Exp. Neurol., 2006, 199, 249-256.
36. Manning-Bog, A.B.; McCormack, A.L.; Purisai, M.G.; Bolin, L.M.; Di Monte, D.A. alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J. Neurosci., 2003, 23, 3095-3099.
37. da Costa, C.A.; Paitel, E.; Vincent, B.; Checler, F. alpha-Synuclein lowers p53-dependent apoptotic response of neuronal cells - Abolishment by 6-hydroxydopamine and implication for Parkinson's disease. J. Biol. Chem., 2002, 277, 50980-50984.
38. Leng, Y.; Chuang, D.M. Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J. Neurosci., 2006, 26, 7502-7512.
39. Kim, T.D.; Paik, S.R.; Yang, C.H. Structural and functional implications of C-terminal regions of alpha-synuclein. Biochemistry, 2002, 41, 13782-13790.
40. Ostrerova, N.; Petrucelli, L.; Farrer, M.; Mehta, N.; Choi, P.; Hardy, J.; Wolozin, B. alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci., 1999, 19, 5782-5791.
41. Souza, J.M.; Giasson, B.I.; Lee, V.M.Y.; Ischiropoulos, H. Chaperone-like activity of synucleins. FEBS Lett., 2000, 474, 116-119.
42. Park, S.M.; Jung, H.Y.; Kim, T.D.; Park, J.H.; Yang, C.H.; Kim, J. Distinct roles of the N-terminal-binding domain and the C- terminal-solubilizing domain of alpha-synuclein, a molecular chaperone. J. Biol. Chem., 2002, 277, 28512-28520.
43. Chandra, S.; Gallardo, G.; Fernandez-Chacón, R.; Schlüter, O.M.; Südhof, T.C. alpha-synuclein cooperates with CSP alpha in preventing neurodegeneration. Cell, 2005, 123, 383-396.
44. Weinreb, P.H.; Zhen, W.; Poon, A.W.; Conway, K.A.; Lansbury, P.T. Jr. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry, 1996, 35, 13709-13715.
45. Wright, P.E.; Dyson, H.J. Intrinsically unstructured proteins: Re- assessing the protein structure-function paradigm. J. Mol. Biol., 1999, 293, 321-331.
46. Uversky, V.N.; Gillespie, J.R.; Fink, A.L. Why are natively unfolded proteins unstructured under physiologic conditions? Proteins-Struct. Funct. Genet., 2000, 41, 415-427.
47. Dyson, H.J.; Wright, P.E. Intrinsically unstructured proteins and their functions. Nat. Rev. Mol. Cell Biol., 2005, 6, 197-208.
48. Uversky, V.N. A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegene- rative disorders. J. Biomol. Struct. Dyn., 2003, 21, 211-234.
49. Eliezer, D.; Kutluay, E.; Bussell, R. Jr.; Browne, G. Conformational properties of alpha-synuclein in its free and lipid- associated states. J. Mol. Biol., 2001, 307, 1061-1073.
50. Perrin, R.J.; Woods, W.S.; Clayton, D.F.; George, J.M. Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. J. Biol. Chem., 2000, 275, 34393-34398.
51. Jao, C.C.; Der-Sarkissian, A.; Chen, J.; Langen, R. Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling. Proc. Natl. Acad. Sci. USA, 2004, 101, 8331-8336.
52. Chandra, S.; Chen, X.C.; Rizo, J.; Jahn, R.; Südhof, T.C. A broken alpha-helix in folded alpha-synuclein. J. Biol. Chem., 2003, 278, 15313-15318.
53. Trexler, A.J.; Rhoades, E. alpha-Synuclein binds large unilamellar vesicles as an extended helix. Biochemistry, 2009, 48, 2304-2306.
54. Georgieva, E.R.; Ramlall, T.F.; Borbat, P.P.; Freed, J.H.; Eliezer, D. Membrane-bound alpha-synuclein forms an extended helix: Long-distance pulsed ESR measurements using vesicles, bicelles, and rodlike micelles. J. Am. Chem. Soc., 2008, 130, 12856-12857.
55. Drescher, M.; Veldhuis, G.; van Rooijen, B.D.; Milikisyants, S.; Subramaniam, V.; Huber, M. Antiparallel arrangement of the helices of vesicle-bound alpha-synuclein. J. Am. Chem. Soc., 2008, 130, 7796.
56. Miake, H.; Mizusawa, H.; Iwatsubo, T.; Hasegawa, M. Biochemical characterization of the core structure of alpha- synuclein filaments. J. Biol. Chem., 2002, 277, 19213-19219.
57. Giasson, B.I.; Murray, I.V.J.; Trojanowski, J.Q.; Lee, V.M.Y. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem., 2001, 276, 2380-2386.
58. Han, H.Y.; Weinreb, P.H.; Lansbury, P.T. The core alzheimers peptide nac forms amyloid fibrils which seed and are seeded by beta-amyloid - is nac a common trigger or target in neurodegenerative disease. Chem. Biol., 1995, 2, 163-169.
59. Heise, H.; Hoyer, W.; Becker, S.; Andronesi, O.C.; Riedel, D.; Baldus, M. Molecular-level secondary structure, polymorphism, and dynamics of full-length alpha-synuclein fibrils studied by solid-state NMR. Proc. Natl. Acad. Sci. USA, 2005, 102, 15871-15876.
60. Vilar, M.; Chou, H.T.; Lührs, T.; Maji, S.K.; Riek-Loher, D.; Verel, R.; Manning, G.; Stahlberg, H.; Riek, R. The fold of alpha- synuclein fibrils. Proc. Natl. Acad. Sci. USA, 2008, 105, 8637-8642.
61. Terry, R.D.; Masliah, E.; Salmon, D.P.; Butters, N.; Deteresa, R.; Hill, R.; Hansen, L.A.; Katzman, R. Physical basis of cognitive alterations in Alzheimers-disease - synapse loss is the major correlate of cognitive impairment. Ann. Neurol., 1991, 30, 572-580.
62. Dodart, J.C.; Meziane, H.; Mathis, C.; Bales, K.R.; Paul, S.M.; Ungerer, A. Behavioral disturbances in transgenic mice overexpressing the V717F beta-amyloid precursor protein. Behav. Neurosci., 1999, 113, 982-990.
63. Moechars, D.; Dewachter, I.; Lorent, K.; Reversé, D.; Baekelandt, V.; Naidu, A.; Tesseur, I.; Spittaels, K.; Van Den Haute, C.; Checler, F.; Godaux, E.; Cordell, B.; Van Leuven, F. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem., 1999, 274, 6483-6492.
64. Lambert, M.P.; Barlow, A.K.; Chromy, B.A.; Edwards, C.; Freed, R.; Liosatos, M.; Morgan, T.E.; Rozovsky, I.; Trommer, B.; Viola, K.L.; Wals, P.; Zhang, C.; Finch, C.E.; Krafft, G.A.; Klein, W.L. Diffusible, nonfibrillar ligands derived from A beta(1-42) are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA, 1998, 95, 6448-6453.
65. Arrasate, M.; Mitra, S.; Schweitzer, E.S.; Segal, M.R.; Finkbeiner, S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature, 2004, 431, 805-810.
66. Lashuel, H.A.; Lansbury, P.T. Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q. Rev. Biophys., 2006, 39, 167-201.
67. Kirkitadze, M.D.; Bitan, G.; Teplow, D.B. Paradigm shifts in Alzheimer's disease and other neuro degenerative disorders: The emerging role of oligomeric assemblies. J. Neurosci. Res., 2002, 69, 567-577.
68. Goldberg, M.S.; Lansbury, P.T. Jr. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat. Cell Biol., 2000, 2, E115-E119.
69. Masuda, M.; Suzuki, N.; Taniguchi, S.; Oikawa, T.; Nonaka, T.; Iwatsubo, T.; Hisanaga, S.; Goedert, M.; Hasegawa, M. Small molecule inhibitors of alpha-synuclein filament assembly. Biochemistry, 2006, 45, 6085-6094.
70. Greffard, S.; Verny, M.; Bonnet, A.-M.; Seilhean, D.; Hauw, J.-J.; Duyckaerts, C. A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death. Neurobiol. Aging, 2010, 31, 99-103.
71. Waxman, E.A.; Giasson, B.I. Molecular mechanisms of alpha- synuclein neurodegeneration. Biochim. Biophys. Acta-Mol. Basis Dis., 2009, 1792, 616-624.
72. Burke, R.E.; Dauer, W.T.; Vonsattel, J.P.G. A critical evaluation of the braak staging scheme for Parkinson's disease. Ann. Neurol., 2008, 64, 485-491.
73. Parkkinen, L.; Kauppinen, T.; Pirttila, T.; Autere, J.M.; Alafuzoff, I. alpha-Synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann. Neurol., 2005, 57, 82-91.
74. Jellinger, K.A. Absence of alpha-synuclein pathology in postencephalitic parkinsonism. Acta Neuropathol., 2009, 118, 371-379
75. Jellinger, K.A. Formation and development of Lewy pathology: a critical update. J. Neurol., 2009, 256 (Suppl 3), 270-279.
76. Markesbery, W.R.; Jicha, G.A.; Liu, H.C.; Schmitt, F.A. Lewy Body pathology in normal elderly subjects. J. Neuropathol. Exp. Neurol., 2009, 68, 816-822.
77. Tompkins, M.M.; Hill, W.D. Contribution of somal Lewy bodies to neuronal death. Brain Res., 1997, 775, 24-29.
78. Kirik, D.; Rosenblad, C.; Burer, C.; Lundberg, C.; Johansen, T.E.; Muzyczka, N.; Mandel, R.J.; Björklund, A. Parkinson-like neurodegeneration induced by targeted overexpression of alpha- synuclein in the nigrostriatal system. J. Neurosci., 2002, 22, 2780-2791.
79. van der Putten, H.; Wiederhold, K.H.; Probst, A.; Barbieri, S.; Mistl, C.; Danner, S.; Kauffmann, S.; Hofele, K.; Spooren, W.; Ruegg, M.A.; Lin, S.; Caroni, P.; Sommer, B.; Tolnay, M.; Bilbe, G. Neuropathology in mice expressing human alpha-synuclein. J. Neurosci., 2000, 20, 6021-6029.
80. Maries, E.; Dass, B.; Collier, T.J.; Kordower, J.H.; Steece-Collier, K. The role of alpha-synuclein in Parkinson's disease: Insights from animal models. Nat. Rev. Neurosci., 2003, 4, 727-738.
81. Bodner, R.A.; Outeiro, T.F.; Altmann, S.; Maxwell, M.M.; Cho, S.H.; Hyman, B.T.; McLean, P.J.; Young, A.B.; Housman, D.E.; Kazantsev, A.G. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc. Natl. Acad. Sci. USA, 2006, 103, 4246-4251.
82. Gosavi, N.; Lee, H.J.; Lee, J.S.; Patel, S.; Lee, S.J. Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J. Biol. Chem., 2002, 277, 48984-48992.
83. Tanaka, M.; Kim, Y.M.; Lee, G.; Junn, E.; Iwatsubo, T.; Mouradian, M.M. Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J. Biol. Chem., 2004, 279, 4625-4631.
84. Karpinar, D.P.; Balija, M.B.; Kügler, S.; Opazo, F.; Rezaei-Ghaleh, N.; Wender, N.; Kim, H.Y.; Taschenberger, G.; Falkenburger, B.H.; Heise, H.; Kumar, A.; Riedel, D.; Fichtner, L.; Voigt, A.; Braus, G.H.; Giller, K.; Becker, S.; Herzig, A.; Baldus, M.; Jäckle, H.; Eimer, S.; Schulz, J.B.; Griesinger, C.; Zweckstetter, M. Prefibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J., 2009, 28, 3256-68.
85. Emadi, S.; Kasturirangan, S.; Wang, M.S.; Schulz, P.; Sierks, M.R. Detecting morphologically distinct oligomeric forms of alpha-synuclein. J. Biol. Chem., 2009, 284, 11048-11058.
86. Conway, K.A.; Lee, S.J.; Rochet, J.C.; Ding, T.T.; Williamson, R.E.; Lansbury, P.T. Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA, 2000, 97, 571-576.
87. Danzer, K.M.; Haasen, D.; Karow, A.R.; Moussaud, S.; Habeck, M.; Giese, A.; Kretzschmar, H.; Hengerer, B.; Kostka, M. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J. Neurosci., 2007, 27, 9220-32.
88. [88] Kayed, R.; Glabe, C.G. In: Conformation-dependent anti-amyloid oligomer antibodies. Amyloid, Prions, and other Protein Aggregates, Pt C; Elsevier Academic Press Inc: San Diego, 2006; Vol. 413, pp 326-344.
89. Kostka, M.; Hogen, T.; Danzer, K.M.; Levin, J.; Habeck, M.; Wirth, A.; Wagner, R.; Glabe, C.G.; Finger, S.; Heinzelmann, U.; Garidel, P.; Duan, W.; Ross, C.A.; Kretzschmar, H.; Giese, A. Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers. J. Biol. Chem., 2008, 283, 10992-11003.
90. Chen, L.; Jin, J.; Davis, J.; Zhou, Y.; Wang, Y.; Liu, J.; Lockhart, P.J.; Zhang, J. Oligomeric alpha-synuclein inhibits tubulin polymerization. Biochem. Biophys. Res. Commun., 2007, 356, 548-53.
91. Wright, J.A.; Wang, X.; Brown, D.R. Unique copper-induced oligomers mediate alpha-synuclein toxicity. FASEB J., 2009, 23, 2384-2393.
92. Zhang, W.; Wang, T.; Pei, Z.; Miller, D.S.; Wu, X.; Block, M.L.; Wilson, B.; Zhang, W.; Zhou, Y.; Hong, J.S.; Zhang, J. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J., 2005, 19, 533-42.
93. Emadi, S.; Barkhordarian, H.; Wang, M.S.; Schulz, P.; Sierks, M.R. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J. Mol. Biol., 2007, 368, 1132-1144.
94. Danzer, K.M.; Krebs, S.K.; Wolff, M.; Birk, G.; Hengerer, B. Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology. J. Neurochem., 2009, 111, 192-203.
95. Yuan, B.; Sierks, M.R. Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cells. Neurosci. Lett., 2009, 459, 16-8.
96. Lomakin, A.; Chung, D.S.; Benedek, G.B.; Kirschner, D.A.; Teplow, D.B. On the nucleation and growth of amyloid beta- protein fibrils: detection of nuclei and quantitation of rate constants. Proc. Natl. Acad. Sci. USA, 1996, 93, 1125-1129.
97. Wood, S.J.; Wypych, J.; Steavenson, S.; Louis, J.C.; Citron, M.; Biere, A.L. alpha-synuclein fibrillogenesis is nucleation-dependent - Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem., 1999, 274, 19509-19512.
98. Qin, Z.; Hu, D.; Han, S.; Hong, D.P.; Fink, A.L. Role of different regions of alpha-synuclein in the assembly of fibrils. Biochemistry, 2007, 46, 13322-13330.
99. Del Mar, C.; Greenbaum, E.A.; Mayne, L.; Englander, S.W.; Woods, V.L. Structure and properties of alpha-synuclein and other amyloids determined at the amino acid level. Proc. Natl. Acad. Sci. USA, 2005, 102, 15477-15482.
100. Der-Sarkissian, A.; Jao, C.C.; Chen, J.; Langen, R. Structural organization of alpha-synuclein fibrils studied by site-directed spin labeling. J. Biol. Chem., 2003, 278, 37530-37535.
101. Serpell, L.C.; Berriman, J.; Jakes, R.; Goedert, M.; Crowther, R.A. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc. Natl. Acad. Sci. USA, 2000, 97, 4897-4902.
102. Uversky, V.N.; Li, J.; Fink, A.L. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem., 2001, 276, 10737-10744.
103. Bertoncini, C.W.; Jung, Y.S.; Fernandez, C.O.; Hoyer, W.; Griesinger, C.; Jovin, T.M.; Zweckstetter, M. Release of long- range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc. Natl. Acad. Sci. USA, 2005, 102, 1430-1435.
104. Pellarin, R.; Caflisch, A. Interpreting the aggregation kinetics of amyloid peptides. J. Mol. Biol., 2006, 360, 882-892.
105. [105] Auer, S.; Meersman, F.; Dobson, C.M.; Vendruscolo, M. A Generic mechanism of emergence of amyloid protofilaments from disordered oligomeric aggregates. PLoS Comput. Biol., 2008, 4(11), e1000222.
106. Cheon, M.; Chang, I.; Mohanty, S.; Luheshi, L.M.; Dobson, C.M.; Vendruscolo, M.; Favrin, G. Structural reorganisation and potential toxicity of oligomeric species formed during the assembly of amyloid fibrils. PLoS Comput. Biol., 2007, 3, 1727-1738.
107. Pellarin, R.; Guarnera, E.; Caflisch, A. Pathways and intermediates of amyloid fibril formation. J. Mol. Biol., 2007, 374, 917-924.
108. Celej, M.S.; Jares-Erijman, E.A.; Jovin, T.M. Fluorescent N- arylaminonaphthalene sulfonate probes for amyloid aggregation of alpha-synuclein. Biophys. J., 2008, 94, 4867-4879.
109. Lindgren, M.; Sörgjerd, K.; Hammarström, P. Detection and characterization of aggregates, prefibrillar amyloidogenic oligomers, and protofibrils using fluorescence spectroscopy. Biophys. J., 2005, 88, 4200-4212.
110. Dusa, A.; Kaylor, J.; Edridge, S.; Bodner, N.; Hong, D.P.; Fink, A.L. Characterization of oligomers during alpha-synuclein aggregation using intrinsic tryptophan fluorescence. Biochemistry, 2006, 45, 2752-2760.
111. Lee, J.H.; Lee, I.H.; Choe, Y.J.; Kang, S.; Kim, H.Y.; Gai, W.P.; Hahn, J.S.; Paik, S.R. Real-time analysis of amyloid fibril formation of alpha-synuclein using a fibrillation-state-specific fluorescent probe of JC-1. Biochem. J., 2009, 418, 311-323.
112. Luk, K.C.; Hyde, E.G.; Trojanowski, J.Q.; Lee, V.M. Sensitive fluorescence polarization technique for rapid screening of alpha- synuclein oligomerization/fibrillization inhibitors. Biochemistry, 2007, 46, 12522-12529.
113. Thirunavukkuarasu, S.; Jares-Erijman, E.A.; Jovin, T.M. Multiparametric fluorescence detection of early stages in the amyloid protein aggregation of pyrene-labeled alpha-synuclein. J. Mol. Biol., 2008, 378, 1064-1073.
114. Kaylor, J.; Bodner, N.; Edridge, S.; Yamin, G.; Hong, D.P.; Fink, A.L. Characterization of oligomeric intermediates in alpha- synuclein fibrillation: FRET studies of Y125W/Y133F/Y136F alpha-synuclein. J. Mol. Biol., 2005, 353, 357-372.
115. Ding, T.T.; Lee, S.J.; Rochet, J.C.; Lansbury, P.T. Annular alpha- synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry, 2002, 41, 10209-10217.
116. Bhak, G.; Lee, J.H.; Hahn, J.S.; Paik, S.R. Granular assembly of alpha-synuclein leading to the accelerated amyloid fibril formation with shear stress. PLoS One, 2009, 4, e4177.
117. Kayed, R.; Pensalfini, A.; Margol, L.; Sokolov, Y.; Sarsoza, F.; Head, E.; Hall, J.; Glabe, C. Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J. Biol. Chem., 2009, 284, 4230-7.
118. Lee, J.H.; Bhak, G.; Lee, S.G.; Paik, S.R. Instantaneous amyloid fibril formation of alpha-synuclein from the oligomeric granular structures in the presence of hexane. Biophys. J., 2008, 95, L16-8.
119. Collins, S.R.; Douglass, A.; Vale, R.D.; Weissman, J.S. Mechanism of prion propagation: Amyloid growth occurs by monomer addition. PLoS Biol., 2004, 2, 1582-1590.
120. Nichols, M.R.; Moss, M.A.; Reed, D.K.; Lin, W.L.; Mukhopadhyay, R.; Hoh, J.H.; Rosenberry, T.L. Growth of beta- amyloid(1-40) protofibrils by monomer elongation and lateral association. Characterization of distinct products by light scattering and atomic force microscopy. Biochemistry, 2002, 41, 6115-6127.
121. Volles, M.J.; Lee, S.J.; Rochet, J.C.; Shtilerman, M.D.; Ding, T.T.; Kessler, J.C.; Lansbury, P.T. Jr. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry, 2001, 40, 7812-7819.
122. Apetri, M.M.; Maiti, N.C.; Zagorski, M.G.; Carey, P.R.; Anderson, V.E. Secondary structure of alpha-synuclein oligomers: Characterization by Raman and atomic force microscopy. J. Mol. Biol., 2006, 355, 63-71.
123. Kim, H.Y.; Cho, M.K.; Kumar, A.; Maier, E.; Siebenhaar, C.; Becker, S.; Fernandez, C.O.; Lashuel, H.A.; Benz, R.; Lange, A.; Zweckstetter, M. Structural properties of pore-forming oligomers of alpha-synuclein. J. Am. Chem. Soc., 2009, 131, 17482-17489.
124. van Rooijen, B.D. van Leijenhorst-Groener, K.A., Claessens, M. M. A. E. and Subramaniam, V. Tryptophan fluorescence reveals structural features of alpha-synuclein oligomers. J. Mol. Biol., 2009, 394, 826-833.
125. Giese, A.; Bader, B.; Bieschke, J.; Schaffar, G.; Odoy, S.; Kahle, P.J.; Haass, C.; Kretzschmar, H. Single particle detection and characterization of synuclein co-aggregation. Biochem. Biophys. Res. Commun., 2005, 333, 1202-1210.
126. Klucken, J.; Outeiro, T.F.; Nguyen, P.; McLean, P.J.; Hyman, B.T. Detection of novel intracellular alpha-synuclein oligomeric species by fluorescence lifetime imaging. FASEB J., 2006, 20, 2050-2057.
127. Outeiro, T.F.; Putcha, P.; Tetzlaff, J.E.; Spoelgen, R.; Koker, M.; Carvalho, F.; Hyman, B.T.; McLean, P.J. Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One, 2008, 3, e1867.
128. Cappai, R.; Leck, S.L.; Tew, D.J.; Williamson, N.A.; Smith, D.P.; Galatis, D.; Sharples, R.A.; Curtain, C.C.; Ali, F.E.; Cherny, R.A.; Culvenor, J.G.; Bottomley, S.P.; Masters, C.L.; Barnham, K.J.; Hill, A.F. Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J., 2005, 19, 1377-1379.
129. Sharon, R.; Bar-Joseph, I.; Frosch, M.P.; Walsh, D.M.; Hamilton, J.A.; Selkoe, D.J. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron, 2003, 37, 583-595.
130. Segers-Nolten, I.M.J.; Wilhelmus, M.M.M.; Veldhuis, G.; Van Rooijen, B.D.; Drukarch, B.; Subramaniam, V. Tissue transglutaminase modulates alpha-synuclein oligomerization. Protein Sci., 2008, 17, 1395-1402.
131. Lowe, R.; Pountney, D.L.; Jensen, P.H.; Gai, W.P.; Voelcker, N.H. Calcium(II) selectively induces alpha-synuclein annular oligomers via interaction with the C-terminal domain. Protein Sci., 2004, 13, 3245-3252.
132. Emmanouilidou, E.; Stefanis, L.; Vekrellis, K. Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome. Neurobiol. Aging, 2010, 31, 953-968.
133. Paleologou, K.E.; Kragh, C.L.; Mann, D.M.; Salem, S.A.; Al-Shami, R.; Allsop, D.; Hassan, A.H.; Jensen, P.H.; El-Agnaf, O.M. Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain, 2009, 132, 1093-1101.
134. Pountney, D.L.; Lowe, R.; Quilty, M.; Vickers, J.C.; Voelcker, N.H.; Gai, W.P. Annular alpha-synuclein species from purified multiple system atrophy inclusions. J. Neurochem., 2004, 90, 502-512.
135. Leng, Y.; Chase, T.N.; Bennett, M.C. Muscarinic receptor stimulation induces translocation of an alpha-synuclein oligomer from plasma membrane to a light vesicle fraction in cytoplasm. J. Biol. Chem., 2001, 276, 28212-28218.
136. Kayed, R.; Head, E.; Thompson, J.L.; McIntire, T.M.; Milton, S.C.; Cotman, C.W.; Glabe, C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science, 2003, 300, 486-489.
137. Quist, A.; Doudevski, I.; Lin, H.; Azimova, R.; Ng, D.; Frangione, B.; Kagan, B.; Ghiso, J.; Lal, R. Amyloid ion channels: a common structural link for protein-misfolding disease. Proc. Natl. Acad. Sci. USA, 2005, 102, 10427-10432.
138. Relini, A.; Torrassa, S.; Rolandi, R.; Gliozzi, A.; Rosano, C.; Canale, C.; Bolognesi, M.; Plakoutsi, G.; Bucciantini, M.; Chiti, F.; Stefani, M. Monitoring the process of HypF fibrillization and liposome permeabilization by protofibrils. J. Mol. Biol., 2004, 338, 943-957.
139. Demuro, A.; Mina, E.; Kayed, R.; Milton, S.C.; Parker, I.; Glabe, C.G. Calcium dysregulation and membrane disruption as aubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem., 2005, 280, 17294-17300.
140. Kayed, R.; Sokolov, Y.; Edmonds, B.; McIntire, T.M.; Milton, S.C.; Hall, J.E.; Glabe, C.G. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem., 2004, 279, 46363-46366.
141. Kourie, J.I.; Henry, C.L. Ion channel formation and membrane- linked pathologies of misfolded hydrophobic proteins: The role of dangerous unchaperoned molecules. Clin. Exp. Pharmacol. Physiol., 2002, 29, 741-753.
142. Arispe, N.; Rojas, E.; Pollard, H.B. Alzheimer-disease amyloid beta-protein forms calcium channels in bilayer-membranes - blockade by tromethamine and aluminum. Proc. Natl. Acad. Sci USA, 1993, 90, 567-571.
143. Lashuel, H.A.; Grillo-Bosch, D. In vitro preparation of prefibrillar intermediates of amyloid-beta and alpha-synuclein. Methods Mol. Biol., 2005, 299, 19-33.
144. Lashuel, H.A.; Petre, B.M.; Wall, J.; Simon, M.; Nowak, R.J.; Walz, T.; Lansbury, P.T. Jr. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol., 2002, 322, 1089-1102.
145. Volles, M.J.; Lansbury, P.T. Jr. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease- linked mutations and occurs by a pore-like mechanism. Biochemistry, 2002, 41, 4595-4602.
146. Sokolov, Y.; Kozak, J.A.; Kayed, R.; Chanturiya, A.; Glabe, C.; Hall, J.E. Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J. Gen. Physiol., 2006, 128, 637-647.
147. Capone, R.; Quiroz, F.G.; Prangkio, P.; Saluja, I.; Sauer, A.M.; Bautista, M.R.; Turner, R.S.; Yang, J.; Mayer, M. Amyloid-beta induced ion flux in artificial lipid bilayers and neuronal cells: resolving a controversy. Neurotox. Res., 2009, 16, 1-13.
148. Tsigelny, I.F.; Bar-On, P.; Sharikov, Y.; Crews, L.; Hashimoto, M.; Miller, M.A.; Keller, S.H.; Platoshyn, O.; Yuan, J.X.; Masliah, E. jen et al. Dynamics of alpha-synuclein aggregation and inhibition of pore- like oligomer development by beta-synuclein. FEBS J., 2007, 274, 1862-1877.
149. Zakharov, S.D.; Hulleman, J.D.; Dutseva, E.A.; Antonenko, Y.N.; Rochet, J.C.; Cramer, W.A. Helical alpha-synuclein forms highly conductive ion channels. Biochemistry, 2007, 46, 14369-14379.
150. Jo, E.; Darabie, A.A.; Han, K.; Tandon, A.; Fraser, P.E.; McLaurin, J. alpha-Synuclein-synaptosomal membrane interactions: implications for fibrillogenesis. Eur. J. Biochem., 2004, 271, 3180-3189.
151. Lee, H.J.; Choi, C.; Lee, S.J. Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem., 2002, 277, 671-678.
152. Zhu, M.; Li, J.; Fink, A.L. The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation. J. Biol. Chem., 2003, 278, 40186-40197.
153. Jo, E.; McLaurin, J.; Yip, C.M.; St George-Hyslop, P.; Fraser, P.E. alpha-Synuclein membrane interactions and lipid specificity. J. Biol. Chem., 2000, 275, 34328-34334.
154. Giannakis, E.; Pacifico, J.; Smith, D.P.; Hung, L.W.; Masters, C.L.; Cappai, R.; Wade, J.D.; Barnham, K.J. Dimeric structures of alpha- synuclein bind preferentially to lipid membranes. Biochim. Biophys. Acta, 2008, 1778, 1112-1119.
155. van Rooijen, B.D.; Claessens, M.M.A.E.; Subramaniam, V. Lipid bilayer disruption by oligomeric alpha-synuclein depends on bilayer charge and accessibility of the hydrophobic core. Biochim. Biophys. Acta, 2009, 1788, 1271-1278.
156. Drescher, M. van Rooijen, B. D. Veldhuis, G. Subramaniam, V. and Huber, M. A Stable lipid induced aggregate of alpha-synuclein. J. Am. Chem. Soc., 2010, 132, 4080-4082.
157. Gai, W.P.; Yuan, H.X.; Li, X.Q.; Power, J.T.H.; Blumbergs, P.C.; Jensen, P.H. In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies. Exp. Neurol., 2000, 166, 324-333.
158. van Rooijen, B.D.; Claessens, M.M.A.E.; Subramaniam, V. Membrane binding of oligomeric alpha-synuclein depends on bilayer charge and packing. FEBS Lett., 2008, 582, 3788-3792.
159. Nuscher, B.; Kamp, F.; Mehnert, T.; Odoy, S.; Haass, C.; Kahle, P.J.; Beyer, K. alpha-synuclein has a high affinity for packing defects in a bilayer membrane - A thermodynamics study. J. Biol. Chem., 2004, 279, 21966-21975.
160. Mach, H.; Middaugh, C.R. Interaction of partially structured states of acidic fibroblast growth-factor with phospholipid-membranes. Biochemistry, 1995, 34, 9913-9920.
161. Halskau, O.; Underhaug, J.; Frøystein, N.A.; Martínez, A. Conformational flexibility of alpha-lactalbumin related to its membrane binding capacity. J. Mol. Biol., 2005, 349, 1072-1086.
162. Song, M.S.; Shao, H.Y.; Mujeeb, A.; James, M.L.; Miller, W.L. Molten-globule structure and membrane binding of the N-terminal protease-resistant domain (63-193) of the steroidogenic acute regulatory protein (StAR). Biochem. J., 2001, 356, 151-158.
163. Smith, D.P.; Tew, D.J.; Hill, A.F.; Bottomley, S.P.; Masters, C.L.; Barnham, K.J.; Cappai, R. Formation of a high affinity lipid- binding intermediate during the early aggregation phase of alpha- synuclein. Biochemistry, 2008, 47, 1425-1434.
164. van Meer, G.; Voelker, D.R.; Feigenson, G.W. Membrane lipids: where they are and how they behave. Nat. Rev. Mol. Cell Biol., 2008, 9, 112-24.